HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma: Increasing evidence suggests that PTCL is characteristically an epigenetic disorder, with several HDAC inhibitors receiving regulatory approvals for the treatment of relapsed/refractory disease.